Below are the financial statements of Novozymes, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of EUR | 2024 2024-01-01 - 2024-12-31 | 2023 2023-01-01 - 2023-12-31 |
|---|---|---|
| Net sales | 3,833.5a | 2,402.2a |
| Cost of goods sold | -2,024a | -1,097.4a |
| Gross profit | 1,809.5a | 1,304.8a |
| Sales and distribution costs | -550.9a | -317.4a |
| Research and development costs | -413.2a | -270.7a |
| Administrative costs | -214.6a | -128.7a |
| Other operating income | 28.2a | 22.9a |
| Operating profit (EBIT) before special items | 659a | 610.9a |
| Special items | -158a | -77.3a |
| Operating profit (EBIT) | 501a | 533.6a |
| Share of result in associates | -3.5a | -2.4a |
| Financial income | 26.9a | 37.8a |
| Financial costs | -107.3a | -44.3a |
| Profit before tax | 417.1a | 524.7a |
| Tax | -111.3a | -116.8a |
| Net profit | 305.8a | 407.9a |
| Attributable to shareholders of Novozymes A/S | 305.8a | 405.9a |
| Non-controlling interests | 0a | 2a |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Novozymes’s data sources below and access millions more through our Disclosure Search.